CD19 and congenital rubella syndrome: Only few patients experienced grade 1/2 CRS and ICANS, which was manageable with small dosages of tocilizumab and corticosteroids, indicating that CD19 CAR T-cells generated using the DNA transposon systems exhibit a better safety profile in comparison to existing virus-generated CD19 CAR T-cell therapies.